Rambam Health Care Campus
Beersheba
What changed
Phase II trial registered: Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease
Apr 2025Trial registeredApr 4, 2025Source filing (opens the source filing in a new tab)
Momentum
Momentum 39 out of 100, unchanged since the last recompute.
Little recent filing activity, or the events on file have decayed.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Phase II
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Trial
PHASE2 registered
Apr 24, 2023Crohn's Disease Relapse, Biological Substance; Adverse Effect · RECRUITING · sponsor: Rambam Health Care Campus · Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease
ClinicalTrials.gov · NCT05599347 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources